위염 시장(2025-2029년)

The global gastritis market is forecasted to grow by USD 1502.4 mn during 2024-2029, accelerating at a CAGR of 4.6% during the forecast period. The report on the global gastritis market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by pervasive helicobacter pylori infection and detrimental lifestyle factors, technological and therapeutic advancements, expanding geriatric population and growing health awareness.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global gastritis market is segmented as below:

By Route Of Administration

• Oral
• Parenteral

By End-User

• Hospitals and clinics
• Specialty centers
• Homecare settings

By Type

• Acute gastritis
• Chronic gastritis
• Erosive gastritis
• Non-erosive gastritis

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Russia
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the paradigm shift in h. pylori eradication therapy driven by antibiotic resistance as one of the prime reasons driving the global gastritis market growth during the next few years. Also, integration of artificial intelligence in endoscopic diagnostics and growing emphasis on advanced non-invasive diagnostic methods will lead to sizable demand in the market.

The report on the global gastritis market covers the following areas:

• Global gastritis market sizing
• Global gastritis market forecast
• Global gastritis market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global gastritis market vendors that include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Cipla Inc., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services, Lupin Ltd., Medtronic Plc, Novartis AG, Otsuka Pharmaceutical Co Ltd., Perrigo Co. Plc, Pfizer Inc., QIAGEN N.V., Sanofi SA, Takeda Pharmaceutical Ltd., Teva Pharmaceutical Ltd., Zydus Lifesciences Ltd.. Also, the global gastritis market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2024
• 4.4 Market outlook: Forecast for 2024-2029

5 Historic Market Size

• 5.1 Global Gastritis Market 2019 - 2023
  • Historic Market Size - Data Table on Global Gastritis Market 2019 - 2023 ($ million)
• 5.2 Route of Administration segment analysis 2019 - 2023
  • Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
• 5.3 End-user segment analysis 2019 - 2023
  • Historic Market Size - End-user Segment 2019 - 2023 ($ million)
• 5.4 Type segment analysis 2019 - 2023
  • Historic Market Size - Type Segment 2019 - 2023 ($ million)
• 5.5 Geography segment analysis 2019 - 2023
  • Historic Market Size - Geography Segment 2019 - 2023 ($ million)
• 5.6 Country segment analysis 2019 - 2023
  • Historic Market Size - Country Segment 2019 - 2023 ($ million)

6 Qualitative Analysis

• 6.1 The AI impact on global gastritis market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2024 and 2029
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2024 and 2029
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2024 and 2029
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2024 and 2029
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2024 and 2029
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2024 and 2029
• 7.7 Market condition

8 Market Segmentation by Route of Administration

• 8.1 Market segments
• 8.2 Comparison by Route of Administration
• 8.3 Oral - Market size and forecast 2024-2029
• 8.4 Parenteral - Market size and forecast 2024-2029
• 8.5 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)

9 Market Segmentation by End-user

• 9.1 Market segments
• 9.2 Comparison by End-user
• 9.3 Hospitals and clinics - Market size and forecast 2024-2029
• 9.4 Specialty centers - Market size and forecast 2024-2029
• 9.5 Homecare settings - Market size and forecast 2024-2029
• 9.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

10 Market Segmentation by Type

• 10.1 Market segments
• 10.2 Comparison by Type
• 10.3 Acute gastritis - Market size and forecast 2024-2029
• 10.4 Chronic gastritis - Market size and forecast 2024-2029
• 10.5 Erosive gastritis - Market size and forecast 2024-2029
• 10.6 Non-erosive gastritis - Market size and forecast 2024-2029
• 10.7 Market opportunity by Type
  • Market opportunity by Type ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2024-2029
  • 12.3.1 US - Market size and forecast 2024-2029
  • 12.3.2 Canada - Market size and forecast 2024-2029
  • 12.3.3 Mexico - Market size and forecast 2024-2029
• 12.4 Europe - Market size and forecast 2024-2029
  • 12.4.1 Germany - Market size and forecast 2024-2029
  • 12.4.2 UK - Market size and forecast 2024-2029
  • 12.4.3 France - Market size and forecast 2024-2029
  • 12.4.4 Italy - Market size and forecast 2024-2029
  • 12.4.5 Spain - Market size and forecast 2024-2029
  • 12.4.6 The Netherlands - Market size and forecast 2024-2029
  • 12.4.7 Russia - Market size and forecast 2024-2029
• 12.5 Asia - Market size and forecast 2024-2029
  • 12.5.1 China - Market size and forecast 2024-2029
  • 12.5.2 Japan - Market size and forecast 2024-2029
  • 12.5.3 India - Market size and forecast 2024-2029
  • 12.5.4 South Korea - Market size and forecast 2024-2029
  • 12.5.5 Indonesia - Market size and forecast 2024-2029
  • 12.5.6 Thailand - Market size and forecast 2024-2029
  • 12.5.7 Singapore - Market size and forecast 2024-2029
• 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
  • 12.6.1 Australia - Market size and forecast 2024-2029
  • 12.6.2 Brazil - Market size and forecast 2024-2029
  • 12.6.3 South Africa - Market size and forecast 2024-2029
  • 12.6.4 UAE - Market size and forecast 2024-2029
  • 12.6.5 Saudi Arabia - Market size and forecast 2024-2029
  • 12.6.6 Turkey - Market size and forecast 2024-2029
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Pervasive helicobacter pylori infection and detrimental lifestyle factors
  • Technological and therapeutic advancements
  • Expanding geriatric population and growing health awareness
• 13.2 Market challenges
  • Escalating antibiotic resistance in helicobacter pylori
  • Diagnostic ambiguity and overlap with functional dyspepsia
  • Concerns over long-term proton pump inhibitor use and genericization
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2024 and 2029
• 13.4 Market opportunities
  • Paradigm shift in h. pylori eradication therapy driven by antibiotic resistance
  • Integration of artificial intelligence in endoscopic diagnostics
  • Growing emphasis on advanced non-invasive diagnostic methods

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Abbott Laboratories
  • Abbott Laboratories - Overview
  • Abbott Laboratories - Business segments
  • Abbott Laboratories - Key news
  • Abbott Laboratories - Key offerings
  • Abbott Laboratories - Segment focus
  • SWOT
• 15.5 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Product / Service
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • SWOT
• 15.6 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product / Service
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • SWOT
• 15.7 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
• 15.8 Dr Reddys Laboratories Ltd.
  • Dr Reddys Laboratories Ltd. - Overview
  • Dr Reddys Laboratories Ltd. - Business segments
  • Dr Reddys Laboratories Ltd. - Key news
  • Dr Reddys Laboratories Ltd. - Key offerings
  • Dr Reddys Laboratories Ltd. - Segment focus
  • SWOT
• 15.9 GlaxoSmithKline Plc
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key news
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Segment focus
  • SWOT
• 15.10 Johnson and Johnson Services
  • Johnson and Johnson Services - Overview
  • Johnson and Johnson Services - Business segments
  • Johnson and Johnson Services - Key news
  • Johnson and Johnson Services - Key offerings
  • Johnson and Johnson Services - Segment focus
  • SWOT
• 15.11 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 15.12 Medtronic Plc
  • Medtronic Plc - Overview
  • Medtronic Plc - Business segments
  • Medtronic Plc - Key news
  • Medtronic Plc - Key offerings
  • Medtronic Plc - Segment focus
  • SWOT
• 15.13 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.14 Otsuka Pharmaceutical Co Ltd.
  • Otsuka Pharmaceutical Co Ltd. - Overview
  • Otsuka Pharmaceutical Co Ltd. - Product / Service
  • Otsuka Pharmaceutical Co Ltd. - Key offerings
  • SWOT
• 15.15 Perrigo Co. Plc
  • Perrigo Co. Plc - Overview
  • Perrigo Co. Plc - Business segments
  • Perrigo Co. Plc - Key offerings
  • Perrigo Co. Plc - Segment focus
  • SWOT
• 15.16 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Product / Service
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • SWOT
• 15.17 QIAGEN N.V.
  • QIAGEN N.V. - Overview
  • QIAGEN N.V. - Product / Service
  • QIAGEN N.V. - Key news
  • QIAGEN N.V. - Key offerings
  • SWOT
• 15.18 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations